Humacyte, Inc.
115 articles with Humacyte, Inc.
-
Humacyte to Present at Upcoming Investor Conferences in March
2/27/2023
Humacyte, Inc. today announced that Laura Niklason, M.D., Ph.D., Chief Executive Officer, and Dale Sander, Chief Financial Officer, will represent Humacyte at the following investor conferences in March.
-
Humacyte Publication in the Journal of Vascular Surgery – Vascular Science Reports the Human Acellular Vessel™ (HAV™) Remains Durable at Six Years in Patients with Peripheral Artery Disease
1/24/2023
Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues and advanced tissue constructs and organ systems at commercial scale, today announced the publication of “6-Year Outcomes of a Phase 2 Study of Human-Tissue Engineered Blood Vessels for Peripheral Arterial Bypass,” in the Journal of Vascular Surgery – Vascular Science.
-
Humacyte Human Acellular Vessel™ (HAV™) Ukraine Humanitarian Results to be Presented at Multiple Vascular Conferences in December 2022
12/1/2022
Humacyte, Inc. today announced presentations on the Company’s Human Acellular Vessel (HAV) by Ukrainian surgeon collaborators.
-
Humacyte to Present at the 34th Annual Piper Sandler Healthcare Conference
11/23/2022
Humacyte, Inc. today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, and Dale Sander, Chief Financial Officer, will participate in a fireside chat at the 34th Annual Piper Sandler Healthcare Conference taking place at the Lotte New York Palace in New York.
-
Humacyte Third Quarter 2022 Financial Results and Business Update
11/10/2022
Humacyte, Inc. announced financial results for the third quarter ended September 30, 2022, and highlighted recent corporate accomplishments.
-
Humacyte Presents Six-Month Human Acellular Vessel™ (HAV™) Coronary Artery Bypass Graft (CABG) Data at the American Heart Association Scientific Sessions 2022 Meeting
11/7/2022
Humacyte, Inc. announced updated six-month results of the HAV in a baboon CABG model.
-
Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 10, 2022
11/3/2022
Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue, complex tissue systems, and organs at commercial scale, will release its financial results for the third quarter ended September 30, 2022, on Thursday, November 10, 2022.
-
Humacyte Announces Presentations by Ukrainian Surgeons on Use of the Human Acellular Vessel™ to Treat Wartime Vascular Trauma at the European Society for Vascular Surgery Annual Meeting
9/23/2022
Humacyte, Inc. today announced the presentation of a clinical update on the Human Acellular Vessel (HAV) for the treatment of vascular trauma.
-
Humacyte Expands Board of Directors and Leadership Team with New Appointments
9/20/2022
Humacyte, Inc. announced the appointments of two distinguished healthcare professionals to the Company’s Board of Directors and leadership team.
-
Humacyte Announces Presentation on Investigational Human Acellular VesselTM for Treatment of Vascular Trauma at the International Committee of Military Medicine World Congress
9/9/2022
Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues, complex tissue systems, and organs at commercial scale, announced the presentation of a clinical update on the Human Acellular Vessel for the treatment of vascular trauma.
-
Humacyte Presents at Multiple Conferences in September 2022
9/8/2022
Humacyte, Inc. announced an oral presentation on the Company’s Human Acellular Vessel by Todd E. Rasmussen, M.D., FACS, at the 44th International Committee on Military Medicine World Congress was given on September 7, 2022.
-
Humacyte to Present Second Quarter 2022 Financial Results and Provide Recent Corporate Update on August 12, 2022
8/5/2022
Humacyte, Inc. will release its financial results for the second quarter ended June 30, 2022, on Friday, August 12, 2022.
-
Humacyte Preclinical Data on Small-Diameter Human Acellular Vessel™ (HAV™) in Coronary Artery Bypass Grafting (CABG) Presented at American Heart Association Meeting
7/26/2022
Humacyte, Inc. announced results evaluating the use of the small-diameter Human Acellular Vessel for coronary artery bypass grafting in a non-human primate model.
-
Humacyte Announces Presentation of Preclinical Data on the HAV™ in Coronary Artery Bypass Grafting at the Basic Cardiovascular Sciences Scientific Sessions
7/19/2022
Humacyte, Inc. (Nasdaq: HUMA), today announced that six-month outcomes from a preclinical study of a small diameter Human Acellular Vessel™ (HAVTM) in coronary artery bypass grafting will be presented at the Basic Cardiovascular Sciences (BCVS) Scientific Sessions taking place in Chicago, IL July 25-28, 2022.
-
Humacyte Hosting Key Opinion Leader Webinar on Human Acellular Vessels™ in the Treatment of Vascular TraumaThursday, July 14, 2022 @ 11:30 a.m. ET
7/7/2022
Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that it will host a key opinion leader (KOL) webinar on its proprietary Human Acellular Vessels (HAV™) in the treatment of vascular trauma on Thursday, July 14, 2022 at 11:30 a.m. Eastern Time.
-
Humacyte Announces JAMA Surgery Publication Highlighting Potential of Human Acellular Vessel™ (HAV™) to Expand Vascular Trauma Reconstruction and Bypass Treatment Options
6/29/2022
Humacyte, Inc. today announced that an analysis of the potential of the Human Acellular Vessel (HAV) to expand vascular surgical treatment options has been published online in the Journal of the American Medical Association (JAMA) companion journal Surgery.
-
Humacyte Expands Board of Directors with Appointment of Diane Seimetz, Ph.D.
6/27/2022
Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the appointment of Diane Seimetz, Ph.D., to its board of directors.
-
Humacyte Provides Update on Patients Treated at Front-Line Hospitals in Ukraine with the Human Acellular Vessel™ (HAV™) for Repair of Vascular Trauma Injuries
6/21/2022
Humacyte, Inc. today announced that the first Ukrainian patients have received implants of the Human Acellular Vessel (HAV) for the treatment of vascular trauma injuries.
-
Humacyte Presents New Immunogenicity Data on Human Acellular Vessels™ (HAVs™)
6/8/2022
Humacyte, Inc. (Nasdaq: HUMA), today presented data on more than 500 patients-years of exposure demonstrating the investigational Human Acellular Vessel (HAV) does not stimulate an increase in calculated panel reactive antibodies (cPRA) or show evidence of PRA sensitization (de novo cPRA > 20 percent) following HAV implantation.
-
Humacyte to Present at the H.C. Wainwright Global Investment Conference
5/16/2022
Humacyte, Inc. announced that Dale Sander, Chief Financial Officer, and Heather Prichard, Ph.D., Chief Operating Officer, will deliver a corporate presentation in-person at the H.C. Wainwright Global Investment Conference taking place both virtually and in-person at the Fontainebleau Hotel in Miami, on May 24, 2022, at 10:30 a.m. ET.